Skip to main content
. 2019 Dec 9;7(1):e000809. doi: 10.1136/bmjdrc-2019-000809

Table 4.

Observed and estimated HbA1c outcomes in the different groups of indications for FSL-FGM use

Indication for FSL-FGM use Baseline 6 months 12 months Difference (12 months)
Hypoglycemia unawareness 1
 Observed 56.6 (50.0 to 63.0) 55.0 (49.0 to 62.0) 55.0 (49.2 to 62.0)
 Estimated 57.4 (55.8 to 59.0) 55.7 (53.6 to 57.9) 56.9 (54.5 to 59.3) −0.5 (–4.0 to 3.0)
 Number 156 86 73
Unexpected hypoglycemias 2
 Observed 58.0 (52.0 to 63.0) 55.0 (50.0 to 61.0)** 55.0 (51.0 to 62.0)**
 Estimated 58.0 (57.2 to 58.9) 55.4 (54.3 to 56.5) 56.2 (55.0 to 57.3) −1.9 (–1.1 to –0.2)
 Number 410 252 218
HbA1c>70 mmol / mol (8.5%) 3
 Observed 76.0 (71.0 to 85.0) 67 (61.0 to 76.8)** 67.5 (61.0 to 76.0)**
 Estimated 79.1 (77.6 to 80.5) 70.0 (67.9 to 72.0) 70.4 (68.3 to 72.6) −8.6 (–11.8 to –5.4)
 Number 294 144 132
Unwanted sensation loss of the fingers 4
 Observed 66.0 (53.0 to 78.0) 61.0 (51.0 to 71.8) 67.5 (58.0 to 73.0)*
 Estimated 68.8 (60.0 to 77.5) 61.6 (49.5 to 73.7) 65.6 (53.5 to 77.7) −3.2 (–21.6 to 15.3)
 Number 19 10 10
Occupational hazards with hypoglycemia 5
 Observed 60.0 (52.5 to 69.0) 56.0 (49.0 to 62.5)* 57.4 (49.3 to 65.5)
 Estimated 64.0 (60.3 to 67.7) 58.0 (53.4 to 62.6) 58.0 (52.7 to 63.3) −5.9 (–13.9 to 2.0)
 Number 57 37 28
Individuals eligible for CGM 6
 Observed 59.0 (51.0 to 67.0) 57.0 (48.5 to 62.0) 61.0 (51.0 to 65.5)
 Estimated 59.1 (55.6 to 62.5) 57.2 (52.7 to 61.7) 59.1 (54.2 to 61.1) 0.1 (–7.3 to 7.5)
 Number 52 43 21
Individuals already using FSL-FGM 7
 Observed 58.5 (53.3 to 67.0) 56.0 (51.5 to 62.0) 56.0 (52.0 to 63.0)
 Estimated 60.4 (58.3 to 62.5) 57.5 (55.0 to 60.1) 58.2 (55.4 to 60.9) −2.2 (–6.4 to 2.0)
 Number 100 65 39
Multiple indications
 Observed 63.0 (54.0 to 71.0) 58.0 (51.0 to 65.0)** 59.0 (52.0 to 66.0)**
 Estimated 63.2 (61.8 to 64.5) 59.0 (57.2 to 60.7) 59.5 (57.7 to 61.4) −3.6 (–6.5 to –0.8)
 Number 283 171 146

Values are presented as numbers, medians (25th, 75th centiles) and estimated means (difference) (95% CI). Data are presented as observed data and estimated data using the linear mixed model. HbA1c concentrations are presented in mmol/mol.

*p<0.05 as compared with baseline; **p<0.001 as compared with baseline. Detailing of indications: see text and Table.

CGM, continuous glucose monitoring; FSL-FGM, FreeStyle Libre flash glucose monitoring.